Advances in the First Line Treatment of Pediatric Acute Myeloid Leukemia in the Polish Pediatric Leukemia and Lymphoma Study Group from 1983 to 2019

Małgorzata Czogała 1,2,*, Walentyna Balwierz 1,2, Katarzyna Pawińska-Wąsikowska 1,2, Teofila Książek 3, Karolina Bukowska-Strakowa 4,*, Wojciech Czogała 2, Barbara Sikorska-Fic 5, Michał Matysiak 5, Jolanta Skalska-Sadowska 6, Jacek Wachowiak 7, Małgorzata Moj-Hackemer 7, Krzysztof Kalwak 7,*, Katarzyna Muszyńska-Roslan 8, Maryna Krawczuk-Rybak 8, Dominik Grabowski 9, Jerzy Kowalczyk 9, Lucyna Maciejka-Kembłowska 10, Ninela Irga-Jaworska 10, Katarzyna Bobeff 11, Wojciech Młynarski 11,*, Renata Tomaszewska 12, Tomasz Szczepański 12,*, Agnieszka Chodała-Grzywacz 13, Grażyna Karolczyk 13, Agnieszka Mizia-Malarz 14,*, Katarzyna Mycko 15, Wanda Badowska 15, Karolina Zielezińska 16, Tomasz Urasiński 16, Justyna Urbanińska-Rakus 17, Małgorzata Ciebiera 18, Radosław Chaber 18,19,*, Natalia Bartoszewicz 20, Mariusz Wysocki 20 and Szymon Skoczeń 1,2,*.*

1 Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, 31-663 Krakow, Poland; malgorzata.czogala@uj.edu.pl (M.C.); walentyna.balwierz@uj.edu.pl (W.B.); katarzyna.pawinska-wasikowska@uj.edu.pl (K.P.-W.)
2 Department of Pediatric Oncology and Hematology, University Children Hospital, 30-663 Krakow, Poland; czogala@tlen.pl
3 Department of Medical Genetics, Institute of Pediatrics, Jagiellonian University Medical College, 31-663 Krakow, Poland; teofilaksiazek@o2.pl
4 Department of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, 31-663 Krakow, Poland; k.bukowska-strakowa@uj.edu.pl
5 Department of Oncology, Pediatric Hematology, Transplantology and Pediatrics, Medical University of Warsaw, 02-091 Warsaw, Poland; basia@poczta.onet.pl (B.S.-F.); michal.matysiak@litewska.edu.pl (M.M.)
6 Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, 60-572 Poznan, Poland; jsk@poczta.onet.eu (J.S.-S.); jacek.wachowiak@plusnet.pl (J.W.)
7 Department of Bone Marrow Transplantation, Pediatric Oncology and Hematology, Wroclaw Medical University, 50-556 Wroclaw, Poland; malgorzata.moj@o2.pl (M.M.-H.); krzysztof.kalwak@umed.wroc.pl (K.K.)
8 Department of Pediatric Oncology and Hematology, Medical University of Białystok, 15-276 Białystok, Poland; kmroslan@umb.edu.pl (K.M.-R.); rybak@umb.edu.pl (M.K.-R.)
9 Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-090 Lublin, Poland; michaldominik@onet.pl (D.G.); jkowalcz@dksl.lublin.pl (J.K.)
10 Department of Pediatrics, Hematology and Oncology, Medical University of Gdańsk, 80-211 Gdańsk, Poland; lucynamacieka@gumed.edu.pl (L.M.-K.); nirga@gumed.edu.pl (N.I.-F.)
11 Department of Pediatrics, Oncology, Hematology and Hematopoiesis, Medical University of Lodz, 91-738 Lodz, Poland; katarzyna.bobeff@umed.lodz.pl (K.B.); wojciech.mlynski@umed.lodz.pl (W.M.)
12 Department of Pediatric Hematology Oncology and Hematology, Medical University of Silesia, 41-800 Zabrze, Poland; rtmaszewska@szpital.zabrze.pl (R.T.); szczep57@poczta.onet.pl (T.S.)
13 Department of Pediatric Hematology and Oncology, Regional Polyclinic Hospital in Kielce, 25-736 Kielce, Poland; aga.chodala@vp.pl (A.C.-G.); grazyka.karolczyk@wszkielce.pl (G.K.)
14 Department of Oncology, Hematology and Chemotherapy, Upper Silesia Children’s Care Health Centre, Medical University of Silesia, 40-752 Katowice, Poland; amzia-malarz@sum.edu.pl
15 Department of Pediatrics and Hematology and Oncology, Province Children’s Hospital, 10-561 Olsztyn, Poland; katarzynamycko@o2.pl (K.M.); hematoonkologia@wssd.olsztyn.pl (W.B.)
16 Department of Pediatrics, Hematology and Oncology, Pomeranian Medical University, 71-252 Szczecin, Poland; katarzyna.zielezińska@wp.pl (K.Z.); urasin@pum.edu.pl (T.U.)
17 Department of Pediatrics, Hematology and Oncology, City Hospital, 41-500 Chorzow, Poland; jku@szm.com.pl
18 Department of Pediatric Oncology and Hematology, Clinical Province Hospital of Rzeszow, 35-301 Rzeszów, Poland; onkohematologia.dzieci@szpital2.rzeszow.pl (M.C.); rchaber@wp.pl (R.C.)
19 Department of Pediatrics, Institute of Medical Sciences, Medical College, University of Rzeszow, 35-310 Rzeszow, Poland
Simple Summary: We retrospectively analyzed the results of the five consecutive treatment protocols for pediatric acute myeloid leukemia (AML) used in Poland from 1983 to 2019 (excluding promyelocytic, secondary, biphenotypic, and Down syndrome AML). The study included 899 children. The probability of three-year overall, event-free, and relapse-free survival increased from 0.34 ± 0.03 to 0.75 ± 0.05, 0.31 ± 0.03 to 0.67 ± 0.05, and 0.52 ± 0.03 to 0.78 ± 0.05, respectively. A systematic reduction of early deaths and deaths in remission was achieved, while the percentage of relapses decreased only in the last therapeutic period. Surprisingly good results were obtained in the group of patients with unfavorable genetic abnormalities like KMT2A-MLLT10/t(10;11)(p12;q23) and DEK-NUP214/t(6;9)(p23;q24) who were treated in the AML-BFM 2012 Registry, while an unsatisfactory outcome was found in patients with FLT3-ITD. The use of standardized therapeutic protocols with the successive consideration of genetic prognostic factors and advances in supportive care led to a significant improvement in AML treatment outcomes over the last 40 years.

Abstract: Background: From 1983, standardized therapeutic protocols for pediatric acute myeloid leukemia (AML) based on the BFM group experience were introduced in Poland. We retrospectively analyzed the results of pediatric AML treatment in Poland from 1983 to 2019 (excluding promyelocytic, therapy-related, biphenotypic, and Down syndrome AML). Methods: The study included 899 children suffering from AML treated with the following: AML-PPPLBC 83 (1983–1993, $n = 187$), AML-PPGLBC 94 (1994–1997, $n = 74$), AML-PPGLBC 98 (1998–2004, $n = 151$), AML-BFM 2004 Interim (2004–2015, $n = 356$), and AML-BFM 2012 (2015–2019, $n = 131$). Results: The probability of three-year overall survival was 0.34 ± 0.03, 0.37 ± 0.05, 0.54 ± 0.04, 0.67 ± 0.03, and 0.75 ± 0.05; event-free survival was 0.31 ± 0.03, 0.34 ± 0.05, 0.44 ± 0.04, 0.53 ± 0.03, and 0.67 ± 0.05; and relapse-free survival was 0.52 ± 0.03, 0.65 ± 0.05, 0.58 ± 0.04, 0.66 ± 0.03, and 0.78 ± 0.05, respectively, in the subsequent periods. A systematic reduction of early deaths and deaths in remission was achieved, while the percentage of relapses decreased only in the last therapeutic period. Surprisingly good results were obtained in the group of patients treated with AML-BFM 2012 with unfavorable genetic abnormalities like KMT2A-MLLT10/t(10;11)(p12;q23) and DEK-NUP214/t(6;9)(p23;q24), while unsatisfactory outcomes were found in the patients with FLT3-ITD. Conclusions: The use of standardized, systematically modified therapeutic protocols, with the successive consideration of genetic prognostic factors, and advances in supportive care led to a significant improvement in AML treatment outcomes over the last 40 years.

Keywords: pediatric acute myeloid leukemia; survival; management

1. Introduction

Acute myeloid leukemia (AML) is a heterogeneous disease with a clonal expansion of myeloid progenitors in the bone marrow and peripheral blood. It comprises about 15% of all leukemias in children. The treatment results in pediatric AML have improved significantly over the last 40 years, and the current overall survival is about 70% [1,2]. A history of unified therapeutic pediatric AML protocols in Poland began in 1983. The Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG) introduced protocol AML-PPLLSG 83, a modified version of Berlin–Frankfurt–Munster (BFM)-AML 83 protocol. The main aim of PPLLSG was to develop diagnostic and treatment standards, and to trial the utility of intensive protocols in Polish conditions. The protocol allowed for increasing the five-year EFS to 32% compared with less than 15% before 1983 [3,4]. However, the results were still significantly worse than the original BFM results [3,5]. The main cause of the difference was a high percentage of early deaths, resulting in a significantly lower remission rate. Insufficient supportive care and toxicities were the main restriction in the introduction
of high doses of cytarabine in the consecutive protocols. In the new protocol (AML-PPLLSG 94) stratification into risk groups was implemented. This caused a slight, but not significant, increase in the event-free survival (EFS) rate (from 32 to 36%) [3,4]. However, the ID-ARAC courses were not effective at producing morphological remissions in late responders and the remission rate did not increase [3]. In the consecutive protocol, AML-PPLLSG 98, a more accurate stratification system was implemented and a new drug, idarubicine, was introduced instead of daunorubicine, for the induction, intensification, and consolidation. Better initial responses were observed in the SR group; however, unsatisfactory treatment outcomes were found in the HR group [3,4].

In 2005, the AML-BFM 2004 Interim protocol was introduced in PPLLSG centers. The stratification to the risk groups was based on the FAB classification, genetic abnormalities, and response to the treatment. Since that time, the central verification of the cell morphology, immunophenotyping, and cytogenetic examination has been available. Since 2006, molecular studies (fusion genes AML1-ETO, PML-RARA, CBFβ-MYH11, MLL-AF4, MLL-AF9, and MLL-ENL, as well as FLT3-ITD and WT1 overexpression) have been performed in the central laboratory in Krakow as the standard diagnostic procedure in all pediatric patients with AML. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from HLA-matched sibling donors was introduced for all patients of the HR group in the first morphological remission, and allo-HSCT from an HLA-matched unrelated donor for children with persistent blasts after the second induction (HAM) or still in aplasia 4 weeks after the second induction. A further improvement of the treatment results, an increase in the proportion of achieved remission, and a reduction of early deaths and deaths in remission was observed; however, the proportion of relapses was still high.

In 2015, a new treatment protocol AML-BFM 2012 was introduced. Stratification to the risk groups was based on cytogenetic and molecular genetics changes. The molecular diagnostic is extended by the HemaVision kit and an analysis of the additional gene mutations (NPM1 and CEBPα). Three risk groups were defined. Cladribine was added for the intermediate and high-risk group in the third chemotherapy course. Hematopoietic stem cell transplantation was indicated in all patients in the high-risk group. A further improvement of the treatment results was achieved.

In parallel with the therapeutic protocol improvements, supportive care also developed, including antifungal prophylaxis, broad spectrum antibiotic in case of neutropenic fever, and guidelines for emergencies like hyperleukocytosis and tumor lysis syndrome.

This is retrospective analysis of the results of the five consecutive treatment protocols for pediatric AML used in Poland from 1983 to 2019.

### 2. Materials and Methods

From 1983 to June 2019, there were 1225 patients from 0 to 18 years old with novo AML diagnosed in Poland. We excluded patients with secondary AML (40), acute promyelocytic leukemia (98), biphenotypic leukemia (23), and patients with Down syndrome myeloid leukemia (68). In addition, 17 patients died before the beginning of the treatment, 15 patients were pretreated with another protocol because of wrong initial diagnosis (acute lymphoblastic leukemia, neuroblastoma), 5 patients could not follow the treatment protocol because of coexisting morbidities, and 16 patients were excluded because of the lack of data. Finally, 899 patients were enrolled in the retrospective analysis. The data were collected through the Polish Acute Myeloid Leukemia Registry.

The patient characteristics are presented in the Table 1.
The patients were treated in 16 Polish pediatric oncology and hematology centers associated with PPLLSG. Five consecutive protocols were used, namely: period I (1983–1993, protocol AML-PPLLSG, 187 patients), period II (1994–1998, AML-PPLLSG 94, 74 patients), period III (1998–2004, AML-PPLLSG 98, 151 patients), period IV (2004–2015, AML-BFM 2004 Interim, 356 patients), and period V (2015–2019, AML-BFM 2012 Registry, 131 patients).

Details of the treatment are presented in Figure 1 and Table 2. Table 3 contains stratification to the risk groups in the periods II–V. Indications for HSCT and the number of patients who underwent the procedure are shown in Table 4.

The patients were treated in 16 Polish pediatric oncology and hematology centers associated with PPLLSG. Five consecutive protocols were used, namely: period I (1983–1993, protocol AML-PPLLSG, 187 patients), period II (1994–1998, AML-PPLLSG 94, 74 patients), period III (1998–2004, AML-PPLLSG 98, 151 patients), period IV (2004–2015, AML-BFM 2004 Interim, 356 patients), and period V (2015–2019, AML-BFM 2012 Registry, 131 patients).

Details of the treatment are presented in Figure 1 and Table 2. Table 3 contains stratification to the risk groups in the periods II–V. Indications for HSCT and the number of patients who underwent the procedure are shown in Table 4.

### Table 1. The patient characteristics.

| Protocol                  | AML-PPLLSG 83 | AML-PPLLSG 94 | AML-PPLLSG 98 | AML-BFM 2004 Interim | AML-BFM 2012 Registry |
|---------------------------|---------------|---------------|---------------|----------------------|-----------------------|
| Period                    | 1983–1993     | 1994–1997     | 1998–2003     | 2004–2014            | 2015–2019             |
| Follow-up end-point       | 31/03/2002    | 31/03/2002    | 31/07/2015    | 31/12/2020           | 31/12/2020            |
| Median observation time (months) | 128         | 93            | 119           | 90                   | 37                    |
| Number of patients        | 187           | 74            | 151           | 356                  | 131                   |
| Age median/range (years)  | 8.2/0.1–16.7  | 10.0/0.4–16.5 | 8.4/0–17.7    | 10.6/0–18            | 7.8/0.1–17.9          |
| Gender male/female        | 93/94         | 36/38         | 87/64         | 184/172              | 73/58                 |
| CNS involvement           | 10 (5.3)      | 5 (6.7)       | 7 (5.8)       | 40 (11.2)            | 13 (9.9)              |
| Extramedullary organ involvement | 40 (21.4)   | 14 (18.9)     | 31 (20.5)     | 88 (24.7)            | 23 (17.5)             |
| FAB types                 |               |               |               |                      |                       |
| M0                        | 0 (0)         | 3 (4.0)       | 12 (8.1)      | 28 (8.1)             | 2 (1.7)               |
| M1                        | 44 (23.5)     | 12 (16.2)     | 27 (18.2)     | 55 (16.0)            | 10 (8.3)              |
| M2                        | 54 (28.9)     | 24 (32.4)     | 52 (35.1)     | 94 (27.3)            | 36 (30.0)             |
| M4                        | 50 (26.7)     | 18 (24.3)     | 29 (19.6)     | 71 (20.6)            | 18 (15.0)             |
| M5                        | 30 (16.0)     | 11 (14.9)     | 19 (12.8)     | 70 (20.3)            | 39 (32.5)             |
| M6                        | 8 (4.3)       | 3 (4.0)       | 6 (4.1)       | 5 (1.4)              | 1 (8.3)               |
| M7                        | 1 (0.5)       | 1 (1.3)       | 3 (2.0)       | 21 (6.1)             | 14 (11.7)             |
| Non defined               | 0 (0)         | 2 (2.7)       | 3 (2.0)       | 12 (3.5)             | 11 (9.2)              |
| Risk groups               |               |               |               |                      |                       |
| SR                        | -             | 30 (40.6)     | 78 (51.7)     | 71 (19.9)            | 25 (18.5)             |
| IR                        | -             | -             | -             | -                    | 52 (40.0)             |
| HR                        | -             | 36 (48.6)     | 65 (43.0)     | 284 (79.8)           | 52 (40.0)             |
| Unknown                   | -             | 8 (10.8)      | 8 (5.3)       | 1 (0.3)              | 2 (1.5)               |

### Table 2. CNS treatment.

| Protocol                  | AML-PPLLSG 83 | AML-PPLLSG 94 | AML-PPLLSG 98 | AML-BFM 2004 Interim | AML-BFM 2012 Registry |
|---------------------------|---------------|---------------|---------------|----------------------|-----------------------|
| CNS irradiation           |               |               |               |                      |                       |
| Cycle                     |               |               |               |                      |                       |
| Consolidation phase 2     |               |               |               |                      |                       |
| HR short postremission block |             |               |               |                      |                       |
| Doses                     |               |               |               |                      |                       |
| 0–1 years                 | 12 Gy         | 12 Gy         | 15 Gy         | 18 Gy                |                      |
| 12 Gy                     | 12 Gy         | 12 Gy         | 15 Gy         | 18 Gy                |                      |
| 1–2 years                 | 15 Gy, 2 Gy   | 15 Gy, 2 Gy   | 18 Gy         | 18 Gy                |                      |
| >2 years                  | >2 Gy         | >2 Gy         | >2 Gy         | >2 Gy                |                      |
| 18 Gy                     | 18 Gy         | 18 Gy         | 18 Gy         | 18 Gy                |                      |
| Instrathelial therapy     |               |               |               |                      |                       |
| Cycle                     |               |               |               |                      |                       |
| consolidation phase 2     |               |               |               |                      |                       |
| SR: consolidation phase 2 days 31, 38, 45, and 51 |               |               |               |                      |                       |
| HR additional doses during AD and AE, and on days 1, 8, and 15 of a short postremission block | | | | | |
| HR: additional dose       |               |               |               |                      |                       |
| HAM day 0                 |               |               |               |                      |                       |
| CSN—central nervous system; SR—standard risk; HR—high risk. Cytarabine monotherapy: 0–1 year, 20 mg; 1–2 years, 26 mg; 2–3 years, 34 mg; >3 years, 40 mg. Triple therapy: cytarabine—0–1 year, 16 mg; 1–2 years, 20 mg; 2–3 years, 26 mg; >3 years, 30 mg; methotrexate—0–1 year, 6 mg; 1–2 years, 8 mg; 2–3 years, 10 mg; >3 years, 12 mg; prednizon—0–1 year, 4 mg; 1–2 years, 6 mg, 2–3 years, 8 mg; >3 years, 10 mg.
Figure 1. Treatment protocols. ADE: cytarabine 100 mg/m²/day continuous infusion on days 1 and 2, followed by 30 min infusion every 12 h on days 3–8; daunorubicin 60 mg/m², 30 min infusion on days 3–5; and etoposide 150 mg/m², 60 min infusion on days 6–8. Consolidation phase 1: 6-thioguanine 60 mg/m²/day, days 1–28, orally; prednisone 60 mg/m²/day, days 1–28, orally; cytarabine 75 mg/m²/day, days 3–6, 10–13, 17–20, 2and 4–27, i.v. or s.c.; vincristine 1.5 mg/m²/day, days 1, 8, 15, and 22; doxorubicin 30 mg/m²/day, days 1, 8, 15, and 22. Consolidation phase 2: 6-thioguanine 60 mg/m²/day, days 29–57 orally; cytarabine 75 mg/m²/day, days 31–34, 38–41, 45–48, and 52–55, i.v. or s.c.; cyclophosphamide 500 mg/m²/day, 60 min infusion on days 29 and 57. ADE*: cytarabine 100 mg/m²/day continuous infusion on days 1 and 2, followed by 30 min infusion every 12 h on days 3–8; daunorubicin 30 mg/m²/dose, 30 min infusion every 12 h on days 3, 4, and 5; etoposide 150 mg/m²/day, 60 min infusion on days 6–8. AD: cytarabine 500 mg/m²/dose, 60 min infusion every 12 h on days 1–5 (10 doses); daunorubicin 30 mg/m²/day, 30 min infusion on days 1, 3, and 5. AE: cytarabine 500 mg/m²/dose, 60 min infusion every 12 h on days 1–5 (10 doses); etoposide 150 mg/m²/day, 60 min infusion on days 6–8. Short post-remission block: 6-thioguanine 60 mg/m²/day on days 1–15, orally; cytarabine 30 mg/m²/day on days 3–6, 10–13, i.v. or s.c.; cyclophosphamide 500 mg/m²/day, 60 min infusion on day 1. AIE: cytarabine 100 mg/m²/day continuous infusion on days 1 and 2, followed by 30 min infusion every 12 h on days 3–8; idarubicin 12 mg/m²/day, 30 min infusion days 3, 4, and 5; etoposide 150 mg/m²/day, 60 min infusion on days 6–8. Consolidation phase 1#: 6-thioguanine 60 mg/m²/day, days 1–28, orally; prednisone 60 mg/m²/day, days 1–28, orally; cytarabine 75 mg/m²/day, days 3–6, 10–13,
17–20, and 24–27, i.v. or s.c.; vincristine 1.5 mg/m²/day, days 1, 8, 15, and 22; idarubicin 12 mg/m²/day, 30 min infusion on days 1, 8, 15, and 22. AI*: cytarabine 500 mg/m²/dose, 60 min infusion every 12 h on days 1–5 (10 doses); idarubicin 12 mg/m²/day, 30 min infusion on days 1, 3, and 5. AI: cytarabine 500 mg/m²/day, 96-hours infusion on days 1–4; idarubicin 12 mg/m²/day, 30 min infusion on days 3 and 5. hAM: cytarabine 1 g/m²/dose, 3 h infusion every 12 h on days 1–3 (6 doses); mitoxantrone 10 mg/m²/day, 30 min infusion on days 3 and 4. HAE: cytarabine 3 g/m²/dose, 3 h infusion every 12 h on days 1–3 (6 doses); etoposide 125 mg/m²/day, 30 min infusion on days 2–5. HAM: cytarabine 3 g/m²/dose, 3 h infusion every 12 h on days 1–3 (6 doses); mitoxantrone 10 mg/m²/day, 30 min infusion on days 3 and 4. AI/2-CDA: cytarabine 500 mg/m²/day, 96-h infusion on days 1–4; idarubicin 12 mg/m²/day, 30 min infusion on days 3 and 5; 2-chloro-2-deoxyadenosine 6 mg/m²/day, 30 min infusion, on days 1 and 3. Maintenance: AML-PPLL 83: Daily thioguanine 40 mg/m²/day, orally; cytarabine 40 mg/m²/day, i.v. or s.c., 4 days every 4 weeks—SR groups for up to 2 years, HR groups received therapy for 1 year (about 18 months of therapy together with intensive courses). AML-BFM 2004 and AML-BFM 2012: daily thioguanine 40 mg/m²/day, orally; cytarabine 40 mg/m²/day, i.v. or s.c., 4 days every 4 weeks for 1 year.

Table 3. Stratification to the risk groups.

| Protocol                  | AML-PPLL 94 | AML-PPLL 98 | AML-BFM 2004 Interim | AML-BFM 2012 Registry |
|---------------------------|-------------|-------------|----------------------|-----------------------|
| **SRG**                   |             |             | M1/M2 with Auer rods | t(8;21), inv(16), t(1;11), NPM1, CEBPαxμ |
| FAB other than M5 and <5% blasts in BM on day 15 |             |             | AML with (8;21) |                         |
| FAB other than M5, <5% blasts in BM on day 15, no increase in blast count after day 15 |             |             | M4E0 with inv16 |                         |
| **IRG**                   |             |             |                      | All others |
| All other patients        |             |             |                      |                         |
| **HRG**                   |             |             | M0 M1/M2 without Auer rods | t(4;11), t(5;11), t(6;11), t(10;11), t(4;9), t(7;12), der12p, isolated monosomy 7, (t9;22), FLT3-ITD-WT1mut, complex karyotype |
| All other patients        |             |             | M4, M5, M6 and M7   |                         |

SRG—standard risk group; IRG—intermediate risk group; HRG—high risk group; BM—bone marrow; a In case of FLT3-ITD—reclassification to HRG; b In case of BM blasts >5% on day 15 or blastic reconstitution between days 15 and 28—reclassification to HRG; c In case of BM blasts >20% on the days 21–28—reclassification to IRG; d In case of BM blast > 20% on the days 21–28 or >5% on the days 42–56—reclassification to HRG.

CSN prophylaxis and therapy are presented in Table 2.

2.1. Diagnostics

The diagnosis was based on bone marrow (BM) examination, including morphology with FAB classification and immunophenotyping. Cytogenetic analyses (both classical and fluorescence in situ hybridization (FISH)) performed in local treatment centers were mandatory from 1998. The results of the karyotype were eligible in 449 patients, including 67 (44%), 267 (75%), and 115 (88%) from periods III, IV, and V, respectively. Since 2005 (period IV and V), central verification of the cell morphology and immunophenotyping examination has been introduced. Moreover, since 2006, molecular studies (fusion genes AML1-ETO, PML-RARA, CBFβ-MYH11, KMT2A-MLLT1, KMT2A–MLLT3, and KMT2A–AFF1) have also been performed in the central Genetic Laboratory of the University Children’s Hospital of Krakow. The results are available for 292 patients from period IV (82%). Since 2015 (period V), the molecular diagnostics has been extended by the HemaVision kit and through analysis of additional gene mutations (NPM1 and CEBPα). These results are available for 125 patients for period V (95%). Analysis of the FLT3-ITD was performed from 2005, and the results for 410 patients are available (278 from period IV (78%) and 129 from period V (100%)).
### Table 4. Hematopoietic stem cell transplantation (HSCT) in the consecutive protocols.

| Protocol | AML-PPLLSG 83 N = 187 | AML-PPLLSG 94 N = 74 | AML-PPLLSG 98 N = 151 | AML-BFM 2004 Interim N = 356 | AML-BFM 2012 Registry N = 131 |
|----------|------------------------|----------------------|------------------------|-------------------------------|-------------------------------|
| Indication for HSCT in the I CR | Very limited access | SRG and HRG: recommended but limited access | SRG: not recommended; HRG: recommended | Allo MSD HSCT: all HRG patients | Allo MSD/MUD HSCT: all HRG patients |
| Number of patients with indications (OS < 4 months and death without CR excluded) | 52 | 245 | 43 |
| HSCT in I CR (% of all patients/ % of patients with indications) | 6 (3) | 13 (18) | 20 (13/38) | 100 (28/41) | 37 (28/86) |
| Auto-HSCT | 0 | 5 | 9 | 1 | 0 |
| Allo-HSCT | 6 | 8 | 11 | 99 | 37 |
| MSD (% of allo) | nd | nd | nd | 50 (53) | 6 (16) |
| MUD (% of allo) | nd | nd | nd | 20 (21) | 22 (59) |
| MMD (% of allo) | nd | nd | nd | 3 (3) | 1 (3) |
| Haplo (% of allo) | nd | nd | nd | 0 | 2 (5) |
| No data | 6 | 8 | 11 | 26 | 6 |

HSCT—hematopoietic stem cell transplantation; HRG—high risk group; SRG—standard risk group; MSD—matched sibling donor; MUD—matched unrelated donor; MMD—mismatched donor; Haplo—HSCT from haploidentical donor; OS—overall survival; CR—complete morphological remission; Allo—allogeneic; Auto—autologous; nd—no data.

The data concerning the cytogenetics and molecular genetics of the patients from periods IV and V are presented in Table 5.

### 2.2. Definitions

Complete morphological remission is defined as less than 5% of blasts in BM demonstrating normal or only slightly decreased cellularity, with signs of regeneration of normal hematopoiesis, regeneration of normal cell production in peripheral blood (≥1000/µL leukocytes, ≥500/µL neutrophil granulocytes and ≥50,000/µL platelets), lack of blasts in peripheral blood, and the disappearance of any extramedullary sites. Minimal residual disease was assessed only in the last period as a part of a separate study; these results did not influence the therapeutic decision and were not analyzed in that paper.

Treatment failure included early death (death during the first 42 days from the start of the treatment); failure to achieve morphological remission on the first line therapy (no fulfillment of CR criteria by the end of intensification; leukemic blasts ≥5% after the second induction; aplasia ≥6 weeks after the beginning of the second induction) and relapse (the reappearance of leukemic blasts in the peripheral blood; re-infiltration of BM with >5% distinct blasts not attributable to any other cause; leukemic infiltration elsewhere following CR; or partial remission lasting at least 4 weeks).
Table 5. Cytogenetics and molecular genetics.

| Protocol                      | AML-BFM 2004 Interim N = 356 | AML-BFM 2012 Registry N = 131 |
|-------------------------------|-------------------------------|-------------------------------|
| Fusion genes—number of results (%) | 292 (82)                     | 125 (95.4)                    |
| Number of positive results (% of available results) | 51 (17.5)                     | 16 (12.8)                     |
| RUNX1-RUNX1T1/t(8;21)(q22;q22) | 12 (4.1)                      | 12 (9.6)                      |
| CBFβ-MYH11/inv(16)(p13;q22)   | 41 (14.0)                     | 37 (29.6)                     |
| All KMT2A rearrangements      |                               |                               |
| KMT2A-ELL/t(11;19)(q23;p13.3) | 1 (0.3)                       | 2 (1.6)                       |
| KMT2A-MLLT1/t(11;19)(q23;p13.3)| 4 (1.4)                       | 1 (0.8)                       |
| KMT2A-MLLT3/t(9;11)(p22;q23)  | 7 (2.4)                       | 14 (11.2)                     |
| KMT2A-MLLT4/t(6;11)(q27;q23)  | 3 (1.0)                       | 3 (2.4)                       |
| KMT2A-MLLT6/t(11;170(q23;q21) | 4 (1.4)                       | 0                             |
| KMT2A-MLLT10/t(10;11)(p12;q23)| 7 (2.4)                       | 16 (12.8)                     |
| KMT2A-AFF1/t(4;11)(q21;q23)   | 1 (0.3)                       | 0                             |
| ETV6-MN1/t(12;22)(p13;q11)    | 0                             | 1 (0.8)                       |
| DEK-NUP214/t(6;9)(p23;q24)    | 3 (1.0)                       | 5 (4.0)                       |
| BCR-ABL1/t(9;22)(q34;q11)     | 1 (0.3)                       | 1 (0.8)                       |
| FLT3-ITD—number of results (%)| 278 (78)                      | 129 (98)                      |
| Positive (% of available)     | 30 (10.8)                     | 11 (8.5)                      |

Statistical analyses were performed with STATISTICA, version 13, StatSoft Inc. Probabilities of survival were calculated using the Kaplan–Meier method. Overall survival (OS) was defined as the time from the date of diagnosis to the date of death from any cause, or from the last follow-up. Event-free survival (EFS) was calculated as the time from diagnosis to the first event (relapse, death of any cause, failure to achieve remission, or secondary malignancy) or last follow-up. Failure to achieve morphological remission was considered an event on day 0. Relapse-free survival (RFS) was calculated as the time from the first remission to the relapse. Probabilities of survival were presented as decimal fractions with standard deviations. The sub-groups were compared with a log-rank test. The relative risks were estimated using a Cox proportional hazard model. The results are presented as a hazard ratio (HR) with a 95% confidence interval (CI). All variables having a p value <0.05 in the univariate analysis were included in a multivariate analysis.

The study was conducted according to the guidelines of the Declaration of Helsinki, and was approved by the Ethics Committee of Jagiellonian University (protocol code: 122.6120.17.2015, date of approval: 29 January 2015). Informed consent was obtained from all patients or guardians when entering each therapeutic protocol.

3. Results

3.1. Treatment Results

The percentage of achieved remissions increased from 72% in period I to 87% in periods IV and V. First-line non-responders comprised 6%, 18%, 10%, 8%, and 7%, respectively. A reduction of early deaths (up to the 42nd day of treatment) was noted, and the percentage decreased systematically in periods I–V from 22% to 5%. Among the patients who achieved remission, the percentage of deaths from toxicities in the following periods decreased from 16% to 1.6%. The rates of relapse were similar in periods I–IV (about 30%) and decreased in the last period to 17% (median follow-up in period V of 37 months; Table 1). The results are presented in Figure 2 and Table 6.
Figure 2. Treatment results. (a) Percentages of early deaths, non-responders, achieved complete morphological remissions in the five consecutive periods. (b) Percentages of deaths in remission, relapses, and patients in continuous complete morphological remission in the five consecutive periods.

Table 6. Treatment results in the five consecutive periods.

| Protocol          | AML-PPLLSG 83 N = 187 | AML-PPLLSG 94 N = 74 | AML-PPLLSG 98 N = 151 | AML-BFM 2004 Interim N = 356 | AML-BFM 2012 Registry N = 131 |
|-------------------|------------------------|-----------------------|------------------------|-------------------------------|-------------------------------|
| Complete morphological remission—CR (%) | 133 (71)               | 49 (66)               | 127 (84)               | 310 (87)                      | 114 (87)                      |
| Non-responders (%) | 9 (5)                  | 15 (20)               | 16 (11)                | 25 (7)                        | 9 (7)                         |
| Early deaths (<42 days) (%) | 45 (24)               | 10 (14)               | 8 (5)                  | 21 (6)                        | 8 (6)                         |
| Deaths in remission (%) | 21 (11)               | 9 (12)                | 14 (9)                 | 18 (5)                        | 2 (1.5)                       |
| Relapses (%)       | 54 (29)                | 17 (23)               | 50 (33)                | 110 (31)                      | 22 (17)                       |
| Continuous remission (%) | 58 (31)               | 23 (31)               | 63 (42)                | 182 (51)                      | 90 (69)                       |

|                      | Probability of 3-years/5-years OS ± SD | Probability of 3-years/5-years EFS ± SD | Probability of 3-years/5-years RFS ± SD |
|----------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|                      | 0.34 ± 0.03/0.31 ± 0.03                | 0.34 ± 0.05/0.30 ± 0.03                | 0.52 ± 0.03/0.51 ± 0.03                |
|                      | 0.54 ± 0.04/0.52 ± 0.04                | 0.44 ± 0.04/0.42 ± 0.04                | 0.58 ± 0.04/0.56 ± 0.04                |
|                      | 0.67 ± 0.03/0.64 ± 0.03                | 0.53 ± 0.03/0.51 ± 0.03                | 0.66 ± 0.03/0.63 ± 0.03                |
|                      | 0.75 ± 0.05/nd                        | 0.67 ± 0.05/nd                        | 0.78 ± 0.05/nd                        |

nd—no data (because of the short follow-up in the last period protocol AML-BFM 2012 Registry), only the probabilities of three-year survival were assessed. OS—overall survival; EFS—event-free survival; RFS—relapse-free survival; SD—standard deviation.

In the subsequent periods, survival improved significantly. The probability of three-year OS increased from 0.34 ± 0.03 to 0.75 ± 0.05, EFS from 0.31 ± 0.03 to 0.67 ± 0.05, and RFS from 0.52 ± 0.03 to 0.78 ± 0.05. The survival curves are presented in Figure 3, and the probabilities of survival are in Table 6.
3.2. Risk Groups

The outcome within the risk groups was analyzed in the last two periods. A comparison of the survival between risk groups was performed separately for each period, as the definition of the risk groups differed across the therapeutic protocols.

According to the AML-BFM 2004 protocol (period IV), two risk groups were distinguished. There were 71 patients (19.9%) in the SRG and 284 children (79.8%) in the HRG (no data in 1 patient). The probability of five-year OS was significantly higher in SRG (0.74 ± 0.04) compared with HRG (0.62 ± 0.03; p = 0.03178). The difference in the probability of EFS was almost significant between SRG and HRG (0.56 ± 0.04 vs. 0.47 ± 0.03; p = 0.0567). No significant differences were found in the probability of RFS (SRG 0.59 ± 0.04, HRG 0.61 ± 0.03). The survival curves are shown in Figure S1.

In period V, three risk groups were defined. There were 25 children in SRG (18.5%), 52 patients in IRG (40%), and 52 in HGR (40%); no data were available concerning two patients. The probabilities of five-year OS were 0.92 ± 0.08, 0.81 ± 0.06, and 0.64 ± 0.06 in SRG, IRG, and HRG, respectively. There was a significant difference in OS between SRG and HRG (p = 0.01296). The probability of five-year EFS was significantly higher in SRG compared with HRG (0.83 ± 0.08 vs. 0.53 ± 0.06; p = 0.01925), with no difference in comparison to IRG (0.69 ± 0.06). No significant difference between the risk groups was noted in terms of RFS (0.83 ± 0.9, 0.71 ± 0.06, and 0.74 ± 0.07 in SRG, IRG, and HRG, respectively). Survival curves are presented in Figure S2.

3.3. The Treatment Results Depending on the Genetics

3.3.1. FLT3-ITD

The analysis was performed only for patients treated with AML-BFM 2004 (period IV) and AML-BFM 2012 (period V) as the results of the FLT3-ITD analysis were not available for the patients from periods I–III. There were 41 FLT3-ITD positive (30 in period IV and 11 in period V) and 366 negative patients (248 in period IV and 118 in he period V).

The probabilities of OS, EFS, and RFS were significantly lower in the FLT3-ITD positive patients compared with the FLT3-ITD negative patients (OS: 0.49 ± 0.08 vs. 0.70 ± 0.02,
There were no significant differences in OS, EFS, and RFS in the FLT3-ITD positive patients, depending on the treatment protocol.

### 3.3.2. Fusion Genes

The results of CBFB-MYH11 and RUNX1-RUNX1T1 were available for most patients treated with AML-BFM 2004 (period IV) and AML-BFM 2012 (period V). There were 24 patients (6%) with the CBFB-MYH11 fusion gene (12 in period IV and 12 in period V). The probabilities of five-year OS, EFS, and RFS were $0.82 \pm 0.08$, $0.65 \pm 0.11$, and $0.74 \pm 0.11$, respectively. The survival curves are presented in Figure S4. No resistant disease was noted in that group of patients. In period IV, there were four relapses and three patients died (all because of toxicities, including one after HSCT in the second remission). In period V, there were no relapses, and one patient died in remission because of severe infection. No significant differences were found in the probabilities of survival between patients treated according to AML-BFM 2004 and AML-BFM 2012 (OS $0.75 \pm 0.12$ vs. $0.92 \pm 0.12$, $p = 0.41516$; EFS $0.50 \pm 0.12$ vs. $0.92 \pm 0.12$, $p = 0.10814$; RFS $0.60 \pm 0.13$ vs. $1.0 \pm 0.13$, $p = 0.09919$).

The RUNX1-RUNX1T1 fusion gene was identified in 66 patients (16%) in the analyzed group (51 in the period IV and 11 in the period V). Only one patient (treated with AML-BFM 2004) did not achieve morphological remission and died in the course of disease progression. Twenty children relapsed (16/51 (31%) in period IV and 4/16 (25%) in period V), including three patients with two relapses (one of them died because of the disease progression). In total, 13 children died—2 of progression (1 non-responder and 1 after second relapse) and 11 of toxicities (4 in the I CR and 7 in the II CR, including 4 after HSCT). All of the deaths occurred in period IV. The probabilities of five-year OS, EFS, and RFS were $0.79 \pm 0.05$, $0.62 \pm 0.06$, and $0.68 \pm 0.06$, respectively. Survival curves are shown in Figure S5. Probability of OS was almost significantly higher in period V compared with period IV ($1.0$ vs. $0.74$, $p = 0.05239$), and no significant differences were found in the probability of EFS and RFS between periods IV and V ($0.61 \pm 0.07$ vs. $0.71 \pm 0.1$ and $0.67 \pm 0.08$ vs. $0.71 \pm 0.12$; Figure S6).

An analysis of survival depending on the other fusions genes was performed only for the patients from period V. In that group, the HemaVision test including 28 fusion genes was used. The results were available for 125 children (95%). Survival curves were done for the fusion genes found in at least five patients, including: CBFB-MYH11 (12 children), RUNX1-RUNX1T1 (16), KMT2A-MLLT10 (16), KMT2A-MLLT3 (14), DEK-NUP214 (5), and for the group of 52 patients with no fusion gene identified with HemaVision. The highest probability of OS was noted for the patients with RUNX1-RUNX1T1 (no deaths), and was significantly higher than in the patients with MLL-MLLT3, MLL-MLLT10, and children with no fusion genes (Figure 4). No other significant differences in OS were found. Patients with CBFB-MYH11 tended to have the highest probability of EFS and RFS. Almost significant differences in the EFS and RFS were noted between children with CBFB-MYH11 and patients with MLL-MLLT3 and without fusion genes (Figure 4).
Figure 4. Probability of survival depending on the fusion genes in patients treated with the AML-BFM 2012 Registry. Probabilities of five-year survival are shown: (a) overall survival; (b) event free survival; (c) relapse free survival.

3.4. Prognostic Factors—Cox Regression Modelling

To assess the significance of potential prognostic factors, Cox regression modelling was performed. The univariate analysis comprised age as the quantitative and qualitative (<2 years, 2–10 years and >10 years) variables, number of white blood cells (WBC) at diagnosis as the quantitative and qualitative (<20,000/µL, 20,000–100,000/µL, and >100,000/µL) variables, and the most common fusion genes or mutations (CBFβ-MYH11, RUNX1-RUNX1T1, MLL-MLLT10, and MLL-MLLT3,FLT3-ITD and WT1) for OS, EFS, and RFS. It revealed that the WT1 mutation, FLT3-ITD, and WBC >100,000/µL at diagnosis predicted a poor outcome, while RUNX1-RUNX1T1 was a favorable prognostic factor. The results are presented in Table 7. In the multivariate analysis, only WBC at diagnosis >100,000/µL remained a significant predictor of poor outcomes (HR for EFS 2.32, 95%CI: 1.20–4.48, \( p = 0.012263 \); HR for OS 2.75, 95%CI 1.28–5.94, \( p = 0.009764 \)).

Table 7. Prognostic factors: Cox regression univariate analysis (significant results).

| Prognostic Factor: Survival Time | HR    | 95% CI           | \( p \)  |
|---------------------------------|-------|-----------------|--------|
| FLT3-ITD: EFS                   | 2.37  | 1.59–3.53       | 0.000023|
| FLT3-ITD: RFS                   | 2.65  | 1.58–4.44       | 0.000233|
| FLT3-ITD: OS                    | 1.85  | 1.15–2.39       | 0.011539|
| WT1 mutation: EFS               | 3.14  | 1.44–6.88       | 0.004167|
| WT1 mutation: RFS               | 3.26  | 1.08–9.84       | 0.036058|
| WT1 mutation: OS                | 3.52  | 1.49–8.30       | 0.004035|
| RUNX1-RUNX1T1: OS              | 0.51  | 0.29–0.90       | 0.020423|
| WBC > 100,000/µL: EFS          | 1.82  | 1.38–2.34       | 0.000017|
| WBC > 100,000/µL: RFS          | 1.94  | 1.34–2.79       | 0.002167|
| WBC > 100,000/µL: OS           | 1.62  | 1.18–2.22       | 0.000363|

HR—hazard ratio; CI—confidence interval; EFS—event free survival; RFS—relapse free survival; OS—overall survival; WBC—number of white blood cells at diagnosis.

3.5. Hematopoietic Stem Cell Transplantation

In the whole analyzed cohort, 173 patients received HSCT in the first CR. As the number of transplantations in the first two periods was low and the data concerning HSCT from that time were lacking, the next analysis considered the children from periods III–V. During that time, HSCT was performed in 157 patients, including 20 in period III, 100 in period IV, and 37 in period V. There were 10 auto-HSCT and 147 allo-HSCT (Table 4).

An analysis of the survival was performed for the patients with event-free survival longer than 4 months (HSCT was performed after at least four chemotherapy cycles, which means after at least 4 months from diagnosis). There was a significant difference in RFS between patients with and without HSCT (five-year RFS 0.74 ± 0.04 vs. 0.62 ± 0.03, \( p = 0.02252 \)), while there were no differences in OS and EFS (five-year OS 0.79 ± 0.03 vs. 0.74 ± 0.02, \( p = 0.20251 \); EFS 0.69 ± 0.03 vs. 0.60 ± 0.02, \( p = 0.14179 \)). Survival curves are shown in Figure 5.
In total, 37/157 patients (27%) died after HSCT in the analyzed period, including 4/20 (20%) patients treated with AML-PPLLSG 98, 26/100 (26%) children treated with AML-BFM 2004, and 7/37 (19%) patients treated with AML-BFM 2012. There were 16 deaths of toxicities after HSCT (10% of all transplanted patient), including 2 (10%), 11 (11%), and 3 (8%) patients from periods III, IV, and V, respectively. Twenty patients (13%) died of progressive disease after HSCT, including 2 (10%), 15 (15%) and 3 (8%) patients treated with consecutive protocols (periods III–V). No significant differences were found in OS, EFS, and RFS in children treated with HSCT depending on the treatment protocols (five-year OS: 0.77 ± 0.11, 0.74 ± 0.03 and 0.80 ± 0.06; EFS: 0.49 ± 0.11, 0.58 ± 0.03, 0.65 ± 0.6; RFS: 0.49 ± 0.12, 0.71 ± 0.04; 0.75 ± 0.07, in periods III, IV, and V, respectively).

4. Discussion

The treatment results in childhood AML in Poland improved significantly during the last 40 years. Probability of OS, EFS, and RSF increased from 0.31 ± 0.03 to 0.75 ± 0.05, from 0.30 ± 0.03 to 0.65 ± 0.05, and from 0.51 ± 0.03 to 0.75 ± 0.05, respectively. At the beginning of the history of unified AML treatment protocols in Poland, a high number of early deaths was observed, leading to a lower percentage of morphological remission. In the protocol AML-PPLLSG 94 with intermediate doses of cytarabine, the percentage of early deaths was reduced; however, the non-responders rate increased. Improvement of the supportive care enabled further intensification of the treatment. Introducing idarubicine in protocol AML-PPLLSG 98 and high-dose cytarabine in AML-BFM 2004 led to a significant decrease of non-responders compared to earlier therapy, and a significant increase of morphological remission. This was consistent with the reports of the BFM Study Group [6,7]. Despite the improvement in the treatment outcome in periods I-IV, the percentage of relapses remained unsatisfactory high. A significant reduction of relapses was observed in the last period (AML-BFM 2012 Registry); however, the follow-up was much shorter (median 37 months) than in previous periods.

In addition to therapeutic protocol improvement, supportive care developed, including antifungal prophylaxis, broad spectrum antibiotic for neutropenic fever, and experience in management with emergencies like hyperleukocytosis or tumor lysis syndrome. All of this contributed to a reduction in early deaths and deaths in remission, and finally to an increase in overall survival. The significant role of supportive care in the improvement of the AML treatment outcome was reported by other authors [2,8–11].

Identification of the prognostic factors enabled stratification to the risk groups. At the beginning, it was based on the treatment response and FAB classification. Further studies of the AML-BFM Group, as well as clinical trials worldwide, revealed the prognostic significance of numerous genetic abnormalities [12–18]. Since introduction of the protocol AML-BFM 2004, genetic abnormalities were taken into account in the stratification to risk groups (t(8;21), inv(16) as a favorable and FLT3-ITD as adverse). In the protocol AML-BFM...
2012, the genetic abnormalities became crucial as the prognostic factors (Table 3). In our study, an analysis of survival within risk groups was performed for the last two periods. In the group treated with AML-BFM 2004 Interim, the probability of five-year OS was significantly higher in the SRG compared to HRG. Difference in the probability of EFS was almost significant between SRG and HRG, while no significant differences were found in the probability of RFS. Similarly, in the protocol AML-BFM 2012 Registry there was a significant difference in the OS and EFS between SRG and HRG, while no significant difference between the risk groups was noted in terms of RFS. According to the risk group criteria, all non-responders were classified to the HRG, which could mainly affect lower EFS or OS in that group, while the HR patients who managed to achieve morphological remission had a similar risk of relapse as the SR patients. The relatively low rate of relapses in the HRG could be the effect of HSCT recommended for the high-risk patients.

Compared with the results of original AML-BFM 2004 protocol published by Creutzig [19] survival in the SRG in our group treated with AML-BFM 2004 Interim was lower (OS $0.89 \pm 0.02$ vs $0.74 \pm 0.04$, EFS $0.71 \pm 0.03$ vs $0.56 \pm 0.04$) while HRG outcome was similar (OS $0.65 \pm 0.03$ vs. $0.62 \pm 0.03$, EFS $0.46 \pm 0.03$ vs. $0.47 \pm 0.03$).

The outcome in the patients treated with AML-BFM 2012 in PPLLSG was comparable to the results reported by the AML-BFM Study Group (three-year OS $75 \pm 0.05$ vs. $0.82 \pm 0.03$ and three-year EFS $0.67 \pm 0.05$ vs. $0.69 \pm 0.04$, respectively) [20].

In our study, the results of the FLT3 analysis were available for 407 patients treated with AML-BFM 2004 and AML-BFM 2012, 41 of which (10%) were FLT3-ITD positive. That is similar to what has been reported by other authors [16,17]. In the Children’s Cancer Group (CCG) study, FLT3-ITD was present in 77 of the 360 tested patients (21%) [16], and in the study performed by the AML-BFM Study Group, this mutation was found in 52 out of the 353 analyzed patients (15%) [17]. In our cohort, the probabilities of OS, EFS, and RFS were significantly lower in the FLT3-ITD positive children compared with the FLT3-ITD negative patients. There were no significant differences in OS, EFS, and RFS in the FLT3-ITD positive patients depending on the treatment protocol (AML-BFM 2004 vs. AML-BFM 2012). The treatment results in the analyzed FLT3-ITD group were similar to the results reported by other authors. In the study published by Nicoreth et al. in the group of 52 FLT3-ITD positive patients treated in Germany with AML-BFM 2004 and AML-BFM 2012, the probability of three-year OS and EFS survival was 0.54 ± 0.07 and 0.39 ± 0.07, respectively [17]. In the CCG study, FLT3-ITD positive patients treated on CCG-2941 and -2961 between September 1995 and December 2001 had four-year OS of 0.33 ± 0.13 [16]. Targeted treatment with FLT3 inhibitors has been studied in the last two decades with promising results [1,21,22]. Midostaurin, one of the first-generation FLT3 inhibitors, is the first tyrosine kinase inhibitor approved by the FDA for AML therapy in the first line, and is now being investigated in combination with chemotherapy in children with newly diagnosed FLT3-mutated AML [23].

Inv(16)(p13q22) is associated with acute myeloid leukemia subtype M4Eo and is known as a favorable prognostic factor. It results in the fusion of CBFB and MYH11 genes. The rearrangement is described in about 8% of pediatric AML [13,24]. In our study, there were 24 patients (6% of children with available results) with the CBFB-MYH11 fusion gene (12 in period IV and 12 in period V). No resistant disease was noted in that group of patients. In period IV, there were four relapses and three patients died (all because of toxicities). In period V, there were no relapses, and one patient died in remission because of severe infection. Probabilities of five-year OS, EFS, and RFS were $0.82 \pm 0.08$, $0.65 \pm 0.11$ and $0.74 \pm 0.11$, respectively. The outcome in patients with inv(16) treated with AML-BFM 2012 seemed to be better compared with the protocol AML-BFM 2004; however, the differences were not statistically significant, probably because of the low number of patients in the subgroups. The results are similar to those reported by other authors [12,13].

Translocation (8;21) with fusion gene RUNX1-RUNXIT1 is well known as a favorable prognostic factor in AML, and is detected in 12–14% of pediatric AML [13,25]. In the protocol, AML-BFM 2004 patients with t(8;21) were classified to SRG, and were treated without
the reinduction with high-dose cytarabine and mitoxantrone to minimize overtreatment. However, it was found that the reduction of the intensity of the treatment caused deterioration of outcome. [24]. Based on this finding, it was recommended to add a reinduction for the patients with t(8;21) in the consecutive protocol AML-BFM 2012. In our cohort, this translocation was found in 67 patients (16% of children with available results), including 51 patients treated with AML-BFM 2004 (period IV) and 16 children treated with AML-BFM 2012 (period V). The probabilities of five-year OS, EFS, and RFS were 0.79 ± 0.05, 0.62 ± 0.06, and 0.68 ± 0.06, respectively. Probability of OS was almost significantly higher in period V compared with period IV. However, despite the treatment intensification in the protocol AML-BFM 2012 (additional reinduction with HAM cycle), no reduction of relapses was noted. No significant differences were found in the probability of EFS and RFS between periods IV and V. Interestingly, the high rate of relapses did not deteriorate the OS. Patients who relapsed still had a favorable prognosis. Improvement in OS survival of patients with t(8;21) in period V compared with period IV was mainly due to a reduction of toxic deaths, probably as a result of better supportive care.

The complex analysis of fusion genes became a standard in the protocol AML-BFM 2012 (HemaVision test including 28 fusion genes). Probability of survival was assessed for the fusion genes found in at least five patients, including: CBFB-MYH11 (12 children), RUNX1-RUNX1T1 (16), KMT2A-MLLT10 (16), KMT2A-MLLT3 (14), DEK-NUP214 (5), and for the group of 52 patients with no fusion gene identified with HemaVision. The most favorable outcome was observed in patients with CBFB-MYH11 and RUNX1-RUNX1T1 (despite the relatively low RFS in RUNX1-RUNX1T1), similarly to what has been reported by other authors [13,18]. Interestingly, outcome in patients with fusion genes known as adverse prognostic factors (KMT2A-MLLT10 and DEK-NUP214) was surprisingly good. KMT2A-MLLT10/t(10;11)(p12;q23) was identified in almost 13% of patients in our cohort, while its occurrence is estimated as being 3% in large cohort studies [13,26]. Probability of five-year OS, EFS, and RFS in the group of patients with KMT2A-MLLT10/t(10;11)(p12;q23) in our research was 0.75 ± 0.09, 0.69 ± 0.09, and 0.84 ± 0.11, respectively. In comparison, in the study of Balgobind et al. involving 98 patients with t(10;11)(p12;q23) treated from 1993 to 2005 in 11 collaborative study groups, the probabilities of OS and EFS were 0.45 ± 0.05 and 0.31 ± 0.05, respectively. t(10;11)(p12;q23) were identified as independent predictors of an unfavorable prognosis [27]. The difference in outcome in that historical study compared with our results could be explained by fact that all patients in our study with that translocation were classified to the HRG with an indication to HSCT. However, HSCT was also performed in the cohort described by Balgobind et al., and this procedure did not predict the EFS or OS in the group of patients with t(10;11)(p12;q23) [27].

Translocation t(6;9)(p23;q24) with DEK-NUP214 was identified in five patients in our cohort. An excellent outcome was observed in that group with a probability of five-year OS, EFS, and RFS of 0.80 ± 0.18, 0.80 ± 0.18, and 1.0 in contrast with the results reported by other authors. However, the number of patients with DEK-NUP214 was limited in our study. In the report from the Children’s Oncology Group assessing 48 patients with t(6;9), the probability of five-year OS, EFS, and disease free survival was 0.39 ± 0.15, 0.32 ± 0.14, and 0.33 ± 0.17%, respectively [28]. It was suggested in the literature that HSCT provides a survival benefit to patients with t(6;9) [28,29]. All five patients with DEK-NUP214 in our study were transplanted, which may explain the favorable outcome.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been shown to benefit patients with HR pediatric AML [1,30,31]. An improvement in supportive care led to a reduction of transplantation-related mortality in the last decades. In our cohort, 173 patients received HSCT in the first CR. Analysis of the survival concerning patients treated with AML-PFLLSG 98, AML-BFM 2004, and AML-BFM 2012 after exclusion of the patients with event-free survival shorter than 4 months revealed an improvement in the probability of RFS in the group with HSCT in the first CR compared with the patients treated without HSCT (five-year RFS 0.74 ± 0.04 vs. 0.62 ± 0.03, p = 0.02252). The percentage of death from
toxicities and from the disease progression was 10% and 13%, respectively. The results are similar to those described by other authors [32,33].

5. Conclusions
The use of standardized, systematically modified therapeutic protocols, with successive consideration of genetic prognostic factors in stratification into risk groups, and advances in supportive care significantly improved AML treatment outcomes over the past 40 years. Currently, the treatment results in pediatric AML in Poland are comparable to the results described by other research groups. Surprisingly good results were obtained in the group of patients with genetic abnormalities known as adverse prognostic factors like KMT2A -MLLT1/(t(10;11)(p12;q23) and DEK-NUP214/(t(6;9)(p23;q24), probably due to appropriate classification to the HRG with HSCT in the first CR. However, an unsatisfactory outcome was still found in the patients with FLT3-ITD. This group of patients may benefit in the future from targeted therapy with FLT3 inhibitors that are currently widely being investigated.

Continued close international cooperation, further improvement of the stratification into risk groups and indications for HSCT based on genetics and MRD assessment, and new drugs (especially targeted treatment) seem to be crucial directions for the future.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13184536/s1. Figure S1: Probability of survival in patients treated with AML-BFM 2004 Interim depending on the risk groups. Figure S2: Probability of survival in patients treated with AML-BFM 2012 Registry depending on the risk groups. Figure S3: Probability of survival depending on FLT3-ITD status in patients treated with AML-BFM 2004 Interim and AML-BFM 2012 Registry. Figure S4: Probability of overall survival (OS), event-free survival (EFS), and relapse free survival (RFS) in patients with CBFB-MYH11/inv(16)(p13;q22) treated with AML-BFM 2004 Interim and AML-BFM 2012 Registry. Figure S5: Probability of overall survival (OS), event-free survival (EFS), and relapse free survival (RFS) in patients with RUNXI-RUNX1T1/(t(8;21)(q22;q22) treated with AML-BFM 2004 Interim and AML-BFM 2012 Registry. Figure S6: Probability of survival in patients with RUNXI-RUNX1T1/(t(8;21)(q22;q22) depending on the treatment protocol AML-BFM 2004 Interim vs. AML-BFM 2012 Registry.

Author Contributions: Conceptualization, M.C. (Małgorzata Czogała), W.B. (Walentyna Balwierz) and S.S.; methodology, M.C. (Małgorzata Czogała), W.B. (Walentyna Balwierz) and S.S.; validation, M.C. (Małgorzata Czogała), W.B. (Walentyna Balwierz) and S.S.; formal analysis, M.C. (Małgorzata Czogała) and W.C.; investigation, M.C. (Małgorzata Czogała), K.P.-W., T.K., B.S.-F., J.S.-S., M.M.-H., K.M.-R., D.G., L.M.-K., K.B., R.T., A.C.-G., A.M.-M., K.M., K.Z., J.U.-R., M.C. (Małgorzata Ciebiera) and N.B.; resources, M.C. (Małgorzata Czogała), K.P.-W., B.S.-F., M.M., J.S.-S., J.W., M.M.-H., K.K., K.M.-R., M.K.-R., D.G., J.K., L.M.-K., N.I.-J., K.B., W.M., R.T., T.S., A.C.-G., G.K., A.M.-M., K.M., W.B. (Wanda Badowska), K.Z., T.U., J.U.-R., M.C. (Małgorzata Ciebiera), R.C., N.B. and M.W.; data curation, M.C. (Małgorzata Czogała) and K.P.-W.; writing—original draft preparation, M.C. (Małgorzata Czogała) and W.C.; writing—review and editing, W.B. (Walentyna Balwierz), S.S., K.P.-W., W.C., T.K., B.S.-F., M.M., J.S.-S., J.W., M.M.-H., K.K., K.M.-R., M.K.-R., D.G., J.K., L.M.-K., N.I.-J., K.B., W.M., R.T., T.S., A.C.-G., G.K., A.M.-M., K.M., W.B. (Wanda Badowska), K.Z., T.U., J.U.-R., M.C. (Małgorzata Ciebiera), R.C., N.B. and M.W.; visualization, M.C. (Małgorzata Czogała); supervision, W.B. (Walentyna Balwierz) and S.S.; project administration, W.B. (Walentyna Balwierz) and S.S.; funding acquisition, W.B. (Walentyna Balwierz), S.S. and M.C. (Małgorzata Czogała). All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by Jagiellonian University, grant number N41/DBS/000185.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and was approved by the Ethics Committee of Jagiellonian University Medical College (protocol code 122.6120.17.2015, date of approval: 29 January 2015).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available upon request from the corresponding author. The data are not publicly available due to privacy and ethical restrictions.
Acknowledgments: We are grateful to the patients and their guardians for participation in the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Zwaan, C.M.; Kolb, E.A.; Reinhardt, D.; Abrahamsson, J.; Adachi, S.; Aplenc, R.; De Bont, E.S.; De Moerloose, B.; Dworzak, M.; Gibson, B.E.; et al. Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J. Clin. Oncol. 2015, 33, 2949–2962. [CrossRef]

2. Rasche, M.; Zimmermann, M.; Borschel, L.; Bourquin, J.P.; Dworzak, M.; Klingebiel, T.; Lehrnbecher, T.; Creutzig, U.; Klusmann, J.H.; Reinhardt, D. Successes and challenges in the treatment of pediatric acute myeloid leukemia: A retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 2018, 32, 2167–2177. [CrossRef] [PubMed]

3. Dłużniewska, A.; Polish Pediatric Leukemia/Lymphoma Study Group (PPLSG); Balwierz, W.; Armana, J.; Balcerska, A.; Chybicka, A.; Kowalczyk, J.; Matsiak, M.; Ochocka, M.; Radwanska, U.; et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia 2005, 19, 2117–2124. [CrossRef]

4. Balwierz, W.; Pawinska-Wasikowska, K.; Klekawka, T.; Czogala, M.; Matsiak, M.; Sic-Koperska, B.; Adamkiewicz-Drozynska, E.; Maciejka-Kapuscinska, L.; Chybicka, A.; Potocka, O.; et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland. Memo. 2013, 6, 54–62. [CrossRef] [PubMed]

5. Creutzig, U.; Ritter, J.; Schellong, G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML BFM-78. Blood 1990, 75, 1932–1940. [CrossRef] [PubMed]

6. Creutzig, U.; Ritter, J.; Zimmermann, M.; Hermann, J.; Gaden, H.; Sawatzki, D.B.; Niemeyer, C.M.; Schwabe, D.; Selle, B.; Boos, J.; et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93. Leukemia 2001, 15, 348–354. [CrossRef] [PubMed]

7. Creutzig, U.; Ritter, J.; Zimmermann, M.; Reinhardt, D.; Hermann, J.; Berthold, F.; AML-BFM Study Group. Improved treatment results in high risk pediatric AML patients after intensification with high dose Ara-C and mitoxantrone: Results of study AML-BFM 93. J. Clin. Oncol. 2001, 19, 2705–2713. [CrossRef] [PubMed]

8. Lehrnbecher, T.; Varwig, D.; Kaiser, J.; Reinhardt, D.; Klingebiel, T.; Creutzig, U. Infectious complications in pediatric acute myeloid leukemia: Analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004, 18, 72–77. [CrossRef]

9. Creutzig, U.; Zimmermann, M.; Reinhardt, D.; Dworzak, M.; Stary, J.; Lehrnbecher, T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J. Clin. Oncol. 2002, 20, 4384–4393. [CrossRef]

10. Jastaniah, W.; Abrar, M.B.; Khattab, T.M. Improved outcome in pediatric AML due to augmented supportive care. Pediatr. Blood Cancer 2012, 10, 919–921. [CrossRef]

11. Bochennek, K.; Hassler, A.; Perner, C.; Gilfert, J.; Schoning, S.; Klingebiel, T.; Reinhardt, D.; Creutzig, U.; Lehrnbecher, T. Infectious complications in children with acute myeloid leukemia: Decreased mortality in multicenter trial AMLBFM 2004. Blood Cancer J. 2016, 6, e682. [CrossRef]

12. von Neuhoff, C.; Reinhardt, D.; Sander, A.; Zimmermann, M.; Bradtke, J.; Betts, D.R.; Zemanova, Z.; Stary, J.; Bourquin, J.P.; Dworzak, M.N.; et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric AML patients treated uniformly according to trial AML-BFM 98. J. Clin. Oncol. 2010, 28, 2682–2689. [CrossRef]

13. Creutzig, U.; Heuvel-Eibrink, M.M.V.D.; Gibson, B.; Dworzak, M.N.; Adachi, S.; De Bont, E.; Harbott, J.; Hasle, H.; Johnston, D.; Kinoshita, A.; et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood 2012, 120, 3187–3205. [CrossRef]

14. Betts, D.R.; Ammann, R.A.; Hirt, A.; Hengartner, H.; Beck-Popovic, M.; Kuhne, T.; Nobile, L.; Cafisch, U.; Wacker, P.; Niggl, F.K. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukemia. A study of the Swiss Paediatric Oncology Group (SPOG). Eur. J. Haematol. 2007, 78, 468–476. [CrossRef] [PubMed]

15. Harrison, C.J.; Hills, R.K.; Moorman, A.V.; Grimwade, D.J.; Hann, I.; Webb, D.K.; Wheatley, K.; de Graaf, S.S.; van den Berg, E.; Burnett, A.K.; et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J. Clin. Oncol. 2010, 28, 2674–2681. [CrossRef]

16. Meshinchi, S.; Alonzo, T.A.; Stirewalt, D.L.; Zwaan, M.; Zimmerman, M.; Reinhardt, D.; Kaspers, G.J.; Heerema, N.A.; Gerbing, R.; Lange, B.J.; et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006, 108, 3564–3601. [CrossRef] [PubMed]

17. Niktoresh, N.; Walter, C.; Zimmermann, M.; von Neuhoff, C.; von Neuhoff, N.; Rusche, M.; Waack, K.; Creutzig, U.; Hanenberg, H.; Reinhardt, D. Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia. J. Oncol. 2019, 2019, 1609128. [CrossRef] [PubMed]

18. Quessada, J.; Cuccuini, W.; Saulnier, P.; Loosveld, M.; Harrison, C.J.; Lafage-Pochitaloff, M. Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge. Genes 2021, 12, 924. [CrossRef]

19. Creutzig, U.; Zimmermann, M.; Bourquin, J.P.; Dworzak, M.N.; Fleischhacker, G.; Graf, N.; Klingebiel, T.; Kremens, B.; Lehrnbecher, T.; Von Neuhoff, C.; et al. Randomized trial comparing posimolan liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from Study AML-BFM 2004. Blood 2013, 122, 37–43. [CrossRef] [PubMed]

20. Waack, K.; Schneider, M.; Walter, C.; Creutzig, U.; Klusmann, J.H.; Rasche, M.; Boztug, H.; Jansen, K.; Escherich, G.; Frühwald, M.; et al. Improved Outcome in Pediatric AML—The AML-BFM 2012 Study. Blood 2020, 136 (Suppl. 1), 12–14. [CrossRef]
21. Stone, R.M.; Mandrekar, S.J.; Sanford, B.L.; Laumann, K.; Geyer, S.; Bloomfield, C.D.; Thiede, C.; Prior, T.W.; Döhner, K.; Marcucci, G.; et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. *N. Engl. J. Med.* 2017, 377, 454–464. [CrossRef]

22. Zwaan, C.M.; Söderhäll, S.; Brethon, B.; Luciani, M.; Rizzari, C.; Stam, R.W.; Besse, E.; Dutreix, C.; Fagioli, F.; Ho, P.A.; et al. A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia. *Br. J. Haematol.* 2019, 185, 623–627. [CrossRef]

23. Chen, J.; Glasser, C.L. New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML). *Children* 2020, 7, 12. [CrossRef]

24. Creutzig, U.; Zimmermann, M.; Bourquin, J.-P.; Dworzak, M.N.; Von Neuhoff, C.; Sander, A.; Schrauder, A.; Teigler-Schlegel, A.; Stary, J.; Corbacho, S.; et al. Second induction with high-dose cytarabine and mitoxantrone: Different impact on pediatric AML patients with t(8;21) and with inv(16). *Blood* 2011, 118, 5409–5415. [CrossRef] [PubMed]

25. Rubnitz, J.E.; Raimondi, S.C.; Halbert, A.R.; Tong, X.; Srivastava, D.K.; Razzouk, B.I.; Pui, C.H.; Downing, J.R.; Ribeiro, R.C.; Behm, F.G. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: A single institution’s experience. *Leukemia* 2002, 16, 2072–2077. [CrossRef] [PubMed]

26. Balgobind, B.V.; Raimondi, S.C.; Harbott, J.; Zimmermann, M.; Alonzo, T.A.; Auvrignon, A.; Beverloo, H.B.; Chang, M.; Creutzig, U.; Dworzak, M.N.; et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: Results of an international retrospective study. *Blood* 2009, 114, 2489–2496. [CrossRef] [PubMed]

27. Tarlock, K.; Alonzo, T.A.; Moraleda, P.P.; Gerbing, R.B.; Raimondi, S.C.; Hirsch, B.A.; Ravindranath, Y.; Lange, B.; Woods, W.G.; Gamis, A.S.; et al. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: A report from the Children’s Oncology Group. *Br. J. Haematol.* 2014, 166, 254–259. [CrossRef]

28. Ishiyama, K.; Takami, A.; Kanda, Y.; Nakao, S.; Maeda, T.; Naoe, T.; Taniguchi, S.; Kawa, K.; Nagamura, T.; Tabuchi, K.; et al. Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant. *Leukemia* 2012, 26, 1416–1419. [CrossRef] [PubMed]

29. Gibson, B.E.S.; Sauer, M.G.; Amrolia, P. Acute Myeloid Leukemia in Children. In *The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies*, 7th ed.; Springer: Cham, Switzerland, 2019; Chapter 70. Available online: https://www.ncbi.nlm.nih.gov/books/NBK554022/ (accessed on 15 July 2021).

30. Wilhelmsson, M.; Glosli, H.; Ifversen, M.; Abrahamsson, J.; Hasle, H. Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: A NOPHO–AML Study. *Bone Marrow Transplant.* 2019, 54, 726–736. [CrossRef] [PubMed]

31. Locatelli, F.; AIEOP BMT Working Group; Masetti, R.; Rondelli, R.; Zecca, M.; Fagioli, F.; Rovelli, A.; Messina, C.; Lanino, E.; Bertaina, A.; et al. Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study. *Bone Marrow Transplant.* 2015, 50, 181–188. [CrossRef] [PubMed]

32. Doherty, E.; Redell, M.; Sasa, G.; Yassine, K.; John, T.D.; Craddock, J.; Wu, M.; Wang, T.; Martinez, C.A.; Krance, R.A.; et al. Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia in the Contemporary Era. *Blood* 2019, 134 (Suppl. 1). [CrossRef]